Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 517,545
  • Shares Outstanding, K 106,272
  • Annual Sales, $ 63,210 K
  • Annual Income, $ -120,550 K
  • 60-Month Beta 1.00
  • Price/Sales 7.11
  • Price/Cash Flow N/A
  • Price/Book 2.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.75
  • Number of Estimates 2
  • High Estimate -0.71
  • Low Estimate -0.80
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -368.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +94.02%
on 12/02/19
5.13 -5.07%
on 12/06/19
+1.02 (+26.49%)
since 11/06/19
3-Month
1.32 +268.94%
on 09/09/19
5.13 -5.07%
on 12/06/19
+3.49 (+252.90%)
since 09/06/19
52-Week
1.13 +332.89%
on 08/02/19
8.39 -41.95%
on 03/13/19
-2.48 (-33.74%)
since 12/06/18

Most Recent Stories

More News
Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated...

LXRX : 4.87 (+15.13%)
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study,...

LXRX : 4.87 (+15.13%)
Lexicon Pharmace Set to Possibly Rebound After Yesterday's Selloff of 11.41%

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $2.51 to a high of $3.18. Yesterday, the shares fell 11.4%, which took the trading range below the 3-day low of $3.46...

LXRX : 4.87 (+15.13%)
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal...

LXRX : 4.87 (+15.13%)
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the...

LXRX : 4.87 (+15.13%)
Lexicon Pharmace Falls 3.08% on Heavy Volume: Watch For Potential Rebound

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $3.58 to a high of $3.83. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $3.75...

LXRX : 4.87 (+15.13%)
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

LXRX : 4.87 (+15.13%)
Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

LXRX : 4.87 (+15.13%)
Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LXRX : 4.87 (+15.13%)
Lexicon: 3Q Earnings Snapshot

THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Thursday reported third-quarter net income of $226.1 million, after reporting a loss in the same period a year earlier.

LXRX : 4.87 (+15.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade LXRX with:

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

2nd Resistance Point 5.66
1st Resistance Point 5.27
Last Price 4.87
1st Support Level 4.34
2nd Support Level 3.80

See More

52-Week High 8.39
Fibonacci 61.8% 5.61
Last Price 4.87
Fibonacci 50% 4.76
Fibonacci 38.2% 3.90
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar